Health Trials

Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Epcoritamab and Rituximab for First-line Follicular Lymphoma

The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Rituximab (a type of monoclonal antibody therapy) * Epcoritamab (a T-cell bispecific antibody)

Participants needed: 100
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Reid Merryman, MDUpdated: May 22, 2026Locations: 6
Eligibility criteria

Histologically confirmed diagnosis of CD20+ FL (grade 1-3A) with review of the d... [+25]

Patients who require systemic immunosuppressive therapy for an ongoing medical c... [+27]

Read more
Status: Recruiting

Epco, Zanu, Ritux for R/R FL or MZL

The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL). * The names of the study drugs involved in this research study are: * Epcoritamab (a type of antibody) * Zanubrutinib (a type of Bruton tyrosine kinase inhibitor) * Rituximab (a type of monoclonal antibody)

Participants needed: 45
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Reid Merryman, MDUpdated: Feb 19, 2026Locations: 3
Eligibility criteria

Histologically confirmed diagnosis of CD20+ FL (grade 1-3A) or CD20+ MZL (any su... [+26]

Patients who require systemic immunosuppressive therapy for an ongoing medical c... [+32]

Read more